TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05655182

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PIV5-vectored RSV Vaccine (BLB-201) Low Dose
Description: BLB201 10\^6 PFU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PIV5-vectored RSV Vaccine (BLB-201) High Dose
Description: BLB201 10\^7 PFU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PIV5-vectored RSV Vaccine (BLB-201) High Dose
Description: BLB201 10\^7 PFU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PIV5-vectored RSV Vaccine (BLB-201) High Dose
Description: BLB201 10\^7 PFU

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo used for the trial will be the same as the diluent (0.9% sterile saline) used for the low dose group (10\^6 PFU).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo used for the trial will be the same as the diluent (0.9% sterile saline) used for the low dose group (10\^6 PFU).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo used for the trial will be the same as the diluent (0.9% sterile saline) used for the low dose group (10\^6 PFU).
Study: NCT04961112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cranial Electrotherapy Stimulation
Description: Participants will receive cranial electrotherapy stimulation stimulation on one of two separate visits (within-subjects).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Cranial Electrotherapy Stimulation
Description: Participants will receive sham stimulation on one of two separate visits (within-subjects).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Cranial Electrotherapy Stimulation
Description: Participants will receive sham stimulation on one of two separate visits (within-subjects).
Study: NCT05655182

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The placebo used for the trial will be the same as the diluent (0.9% sterile saline) used for the low dose group (10\^6 PFU).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo used for the trial will be the same as the diluent (0.9% sterile saline) used for the low dose group (10\^6 PFU).
Study: NCT04991311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glepaglutide
Description: Glepaglutide will be delivered in a single-use autoinjector.
Study: NCT06458712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSB2455
Description: PARP1 inhibitor
Study: NCT06572280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PNS group
Description: non-invasive phrenic nerve stimulation
Study: NCT06395285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF-003
Description: 140 mg on Days 1, 2, and 3 followed by a maintenance dose of 45 mg QD starting on Day 4 through Day 28. DF-003 will be administered PO with approximately 240 mL of water in the morning once daily for 28 consecutive days.
Study: NCT06574100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: Patients in the first arm cross-over will receive either a single bolus dose of 250mg buccally administered or 1000mg CBD powder and cross over to vice-versa after 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: Patients will be randomised to receive 3000mg oral CBD fasting or Fed, they will the cross over to the other group 21 days following the first administration.
Study: NCT05933226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Khanya
Description: Khanya is a peer-delivered, behavioral intervention to improve HIV medication adherence and reduce problematic SUD symptoms. Participants will either receive Khanya Step 1 or if they continue to struggle with ART adherence, they will be stepped up to the more intensive intervention, Khanya Step 2.
Study: NCT06500052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-M17D1
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT05871164

Intervention type: PROCEDURE
Intervention: Pancreatic radiofrequency
Description: Pancreatic radiofrequency is similar to a puncture under echoendoscopy. The lesion is located then punctured by transgastric or transduodenal route either using a 19 gauge needle with exchange of the stylet for a probe, or using a 19 gauge needle whose distal end of 5-10 mm corresponds to the active part, connected to a generator with an integrated cooling system.
Study: NCT06296342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to information framing message
Description: The information framing message presents the objective of the front-of-package labeling policy as providing nutritional information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to healthier choices framing message
Description: The healthier choices framing message presents the objective of the front-of-package labeling policy as encouraging consumers to make healthier choices.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to industry framing message
Description: The industry framing message presents the objective of the front-of-package labeling policy as encouraging the food industry to make healthier products.
Study: NCT04642105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensor-Dot and Plug 'n Patch system
Description: We will use a small, unobtrusive wearable (Sensor-Dot) to measure different biosignals (EEG, ECG, EMG, motion, skin temperature, respiration and oxygen saturation) for up to one year using newly developed skin adhesives and patches (Plug 'n Patch system)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensor-Dot and Plug 'n Patch system
Description: We will use a small, unobtrusive wearable (Sensor-Dot) to measure different biosignals (EEG, ECG, EMG, motion, skin temperature, respiration and oxygen saturation) for up to one year using newly developed skin adhesives and patches (Plug 'n Patch system)
Study: NCT05640934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: The patients will be given 5 mg melatonin the night before surgery, 12 hours before the scheduled time of surgery, followed by another 5 mg melatonin two hours before surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients will be premedicated with placebo tablets, which will be administered at the same times as the melatonin group.
Study: NCT06208618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education and Motivational Interviews
Description: The diabetes education aimed at supporting diabetes self-management in adolescents will include the following topics:~* What is Diabetes?~* Treatment in Diabetes~* Insulin Therapy~* Nutritional Therapy~* Physical Activity/Exercise~* Acute Complications of Diabetes~  * Hypoglycemia~ * Hyperglycemia~ * Diabetic Ketoacidosis~* Diabetes Management in Illness~Motivational interviews will consist of the following stages:~* First Meeting - Pre-awareness (Pre-contemplation)~* Second Meeting - Awareness (Contemplation)~* Third Meeting - Preparation~* Fourth Meeting - Taking Action (Action)~* Fifth Meeting - Maintenance~* Sixth Meeting - Termination or Review
Study: NCT05777369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2, d0
Study: NCT05344105

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy)
Description: A low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy) device will be used while blocking in both groups.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy)
Description: A low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy) device will be used while blocking in both groups.
Study: NCT05888376

Intervention type: DEVICE
Intervention: Vascular access catheter to support dialysis or CRRT
Description: A specialised vascular access catheter to support bi-directional blood flow at high rates to allow extracorporeal removal of toxins by dialysis or CRRT

Intervention type: DEVICE
Intervention: Vascular access catheter to support dialysis or CRRT
Description: A specialised vascular access catheter to support bi-directional blood flow at high rates to allow extracorporeal removal of toxins by dialysis or CRRT

Intervention type: DEVICE
Intervention: Vascular access catheter to support dialysis or CRRT
Description: A specialised vascular access catheter to support bi-directional blood flow at high rates to allow extracorporeal removal of toxins by dialysis or CRRT
Study: NCT06039332

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fitting of the audioprocessor with the auditory implant BCI602
Description: to compare the performance with BB system in two fitting-configurations (active comparator: DSL v5, experimental: DSL-BCD) using audiometric and subjective measures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fitting of the audioprocessor with the auditory implant BCI602
Description: to compare the performance with BB system in two fitting-configurations (active comparator: DSL v5, experimental: DSL-BCD) using audiometric and subjective measures
Study: NCT06381219

Intervention type: OTHER
Group type: OTHER
Intervention: Implementation of cow's milk in decreasingly heated forms
Description: Implementation of cow's milk in decreasingly heated forms to assess maintained remission of EoE

Intervention type: OTHER
Group type: OTHER
Intervention: Implementation of hen's egg in decreasingly heated forms
Description: Implementation of hen's egg in decreasingly heated forms to assess maintained remission of EoE
Study: NCT05774808

Intervention type: PROCEDURE
Intervention: Aortic valve replacement
Description: An aortic valve prosthesis is surgically implanted to treat AR

Intervention type: PROCEDURE
Intervention: Aortic valve replacement
Description: An aortic valve prosthesis is surgically implanted to treat AR

Intervention type: PROCEDURE
Intervention: Mitral valve annuloplasty
Description: Surgical repair of the mitral valve in which a prosthetic ring is implanted to treat MR
Study: NCT06531746

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave
Description: participants will receive 2000 ESWT impulses, with 1500 targeting the taut band and 500 surrounding the taut band, with an energy flux density of 0.10 mJ/mm and frequency of 8 Hz, by using an~EME S.r.l. via Degli Abeti 88/161122 Pesaro \[serial number:~EM12681015\], Italy, shock wave generator.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selected physical therapy program
Description: Stretching and strengthening of Iliopoas muscle and Stretching and strengthening of Lower back muscles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selected physical therapy program
Description: Stretching and strengthening of Iliopoas muscle and Stretching and strengthening of Lower back muscles
Study: NCT06532539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel and Cisplatin
Description: Paclitaxel and Cisplatin Paclitaxel: 135 mg/m², intravenous infusion, Day 1, every 3 weeks (Q3W). Cisplatin: 75 mg/m², intravenous infusion, Days 1-3, every 3 weeks (Q3W). Duration: 6-8 cycles, until disease progression or intolerable adverse effects as judged by the investigator.~Alternative: If contraindicated for cisplatin, or if there is an allergy to paclitaxel and/or cisplatin, alternative drugs such as different types of paclitaxel or carboplatin can be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Cadonilimab: 5-10 mg/kg, intravenous infusion, Day 1, every 3 weeks (Q3W). Duration: Continuous administration until disease progression, death, intolerable toxicity, subject's voluntary withdrawal, investigator's decision for withdrawal, or a maximum of 24 months.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Site Selection: Original site, lymph nodes, lung metastasis, bone metastasis, adrenal metastasis, brain metastasis, and other relatively isolated, well-vascularized lesions. Select at least one suitable lesion for radiotherapy based on the impact of the recurrent or metastatic lesion on the body, prioritizing lesions that cause symptoms, are life-threatening, or are expected to cause symptoms.All tumor lesions will be irradiated, which can be done in phases.~Dosage and Fractionation: Conventional or hypofractionated radiotherapy, with a biologically effective dose (BED) of ≥ 72 Gy. Dose adjustments can be made for brain metastases.~Timing: After completing relevant baseline examinations, radiotherapy can be implemented generally after 2-6 cycles of systemic therapy, or after the first cycle for small, solitary metastatic lesions.~echnique: IMRT, TOMO, SBRT, 3D-BT, interstitial implantation therapy, or proton therapy.
Study: NCT05494879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: microkinesitherapy treatment
Description: The therapeutic session of microkinesitherapy included a seeking of body scares both taking into account somatic dysfunctions as well as psychosomatic disorders. According to the creators of the method, Grosjean and Benini Everything that happens with us in a toxic level, either physically or emotionally, are stored by the brain which keeps memories and generates links that may harm the function of the cells generating a vast array of symptoms and dysfunctions.
Study: NCT05522140

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nature-based social intervention (NBIS)
Description: Nature-based social prescribing is a multicomponent, multi-level, behaviorally based complex intervention applaied by facilitators after a specific training. It comprises: a psychosocial component and nature-based activities. The psychosocial component is adapted from the group dynamic of Circle of Friends methodolgy focused on loneliness(Jansson A, Pitkälä KH, 2021) adapted to the cultural context of Prague and the target population (partitipants) of adults who lives in Prague. Participants start with an individual session and then meet once a week for two hours for 10 weeks.~At the first meeting together, participants select the nature-based activities they wish to conduct through a co-created menu.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care + menu with nature based activities
Description: Social prescribing as existing in usual care plus a written menu with the list of nature-based activities in the area.
Study: NCT03939273

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin Oral
Description: 500 mg thrice per day for seven days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Oral
Description: 500 mg thrice per day for seven days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin Pill
Description: 500 mg twice per day for seven days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole Oral Product
Description: 200 mg once per day for six days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: seven day course of placebo tablets and capsules identical in appearance and number to active treatment
Study: NCT05777369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone hydrochloride liposome
Description: 18 mg/m2, d1
Study: NCT06534073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Socks
Description: Plantar orthotic elements will be designed, according to the participants' previous baropodometric pattern, to alleviate pathological plantar pressure. These elements will be integrated into commonly worn items by patients, such as stockings or socks.

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard device
Description: Removable device of digital alignment to stabilize and unload the affected metatarsophalangeal joint. They do not require frequent replacement as they are washable and reusable elements.

Intervention type: DEVICE
Group type: OTHER
Intervention: Foot orthoses
Description: Custom-made foot orthoses.
Study: NCT05777369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2, d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine/Vindesine
Description: Vincristine: 1.4 mg/m2, d1(The maximum dose was 2 mg) Vindesine: 3 mg/m2, d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 60 mg/m2, d1\~d5
Study: NCT04750928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib is to be administered orally on Days 1 through 28 of each 28-day cycle
Study: NCT04689386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group I (GE-I) - Stimulation of reflex rolling from the Vojta method
Description: This manoeuvre does not require the newborn to be moved, but only a slight rotation of the head towards the side from which the stimulus is delivered. The starting position for performing the first phase of reflex rolling is the asymmetric supine position, with the limbs freely lying on the resting surface.~A digital pressure will exert on the chest area, where the mammillary line crosses the insertion of the diaphragm, either at the level of the 6th rib, or between the 5th and the 6th, or between the 6th and the 7th. A one minute stimulus will be performed on each side. The intervention will be repeated twice a day, ensuring that the period between one intervention and another is at least two hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group II (GE-II) - expiratory flow increase technique
Description: The technique adapted to the premature infant will be performed. This maneuver consists of slowly applying light pressure to the infant's chest with one hand, obliquely, starting from the end of the inspiratory plateau until the end of expiration, which is prolonged. The hand should be placed between the sternal notch and the xiphoid process of the newborn's sternum. The therapist's other hand is placed on the last ribs (without applying pressure) as a bridge, of which the columns are the thumb and forefinger (or middle finger). Therefore, contact with the infant's abdomen is avoided and the expansion of the lower rib is limited, allowing a better displacement of the diaphragm and avoiding an increase in intra-abdominal pressure. The maneuver will be repeated three times, respecting the infant's responses and their physiological constants. The intervention will be repeated twice a day, trying to ensure that the period between one intervention and another is at least 2 hours.
Study: NCT06147609

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lower lingual holding arch space maintainer
Description: lower lingual holding arch space maintainer is an orthodontic device which connects two molars lower dental arch. it has an archwire, adapted to the lingual side of the lower anterior teeth, that soldered to the bands on first permanent molar

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Removable partial denture space maintainer
Description: Removable Partial Denture consists of a pink or gum-colored plastic base to which the new, artificial, replacement teeth are attached to. a metal framework holds the denture in place inside the mouth
Study: NCT06191380

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PACE-MS
Description: A single bout of cycling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACE-MS
Description: A single bout of cycling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACE-MS
Description: A single bout of cycling.
Study: NCT04304846

Intervention type: OTHER
Intervention: Questionnaires and interviews
Description: List of questionnaires: ASQ, PSI, PPQ, SDQ, GSA and AMMI score obtained from mother during two separated interviews for the mother and the child at 3 and 5 years old
Study: NCT05005676

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: acceleromyography
Description: Simultaneous measurement of the time course of a neuromuscular block with 2 acceleromyographs

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: acceleromyography
Description: Simultaneous measurement of the time course of a neuromuscular block with 2 acceleromyographs
Study: NCT06567587

Intervention type: DRUG
Intervention: Dexmedetomidine
Description: Effect o dexmedetomine on agitated normal and psychotic patients on BIPAP who are suffer exaggerated COPD

Intervention type: DRUG
Intervention: Dexmedetomidine
Description: Effect o dexmedetomine on agitated normal and psychotic patients on BIPAP who are suffer exaggerated COPD
Study: NCT05663125

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser interstitial thermal therapy
Description: Ablation of the tumor will be done by MRI-guided laser interstitial thermal therapy with the assistance of neuro-navigation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be administered continuously from the 1st to the 21st day after LITT surgery. The oral dose of temozolomide is 75 mg/m2. And then, it will be given at a routine dose from the second month after surgery.
Study: NCT05364866

Intervention type: DRUG
Intervention: Antiarrhythmic drug Therapy
Description: Propafenone, Sotalol and Amiodarone

Intervention type: DEVICE
Intervention: cryoballoon ablation
Description: Medtronic Arctic Front Advance™ Cardiac CryoAblation Catheters including 23mm and 28mm.
Study: NCT04310202

Intervention type: OTHER
Intervention: Abbreviated Profile of Hearing Aid Benefit (APHAB)
Description: An intervention in this study which is outside the routine clinical practice of the clinics is the APHAB questionnaire that will be completed by the subjects on two occasions.

Intervention type: OTHER
Intervention: Glasgow Benefit Inventory (GBI)
Description: An intervention in this study which is outside the routine clinical practice of the clinics is the GBI questionnaire that will be completed by the subjects on two occasions.

Intervention type: OTHER
Intervention: Additional follow-up visits after surgery
Description: There are 1-2 additional follow-up visits after surgery (compared to the routine clinical practice of the surgeons/clinics).
Study: NCT06567587

Intervention type: DEVICE
Intervention: BIPAP
Description: Put exaggerated COPD patients on non invasive ventillation

Intervention type: DEVICE
Intervention: BIPAP
Description: Put exaggerated COPD patients on non invasive ventillation